Abstract:Background and purpose: The immunogenic drugs represented by programmed cell death 1 (PD-1) and programmed death ligand-1 (PD-L1) have achieved great success in clinic. However, with the development of clinical application, the overall effective rate varies greatly. At present, detection of the expression of PD-1/PD-L1 before the start of tumor treatment is an important basis for clinical medication. However, the current detection method of PD-L1 expression requires the acquisition of patient specimens, which is traumatic. Therefore, there is an urgent need to develop a noninvasive method to detect PD-L1 expression in vivo. This study innovatively designed and synthesized a new positron emission tomography (PET) imaging agent targeting PD-L1 polypeptide 68Ga-DOTA-PDL1P. In this study, the labeling rate, radiochemical purity and stability of 68Ga-DOTA-PDL1P were evaluated for quality control. And the application was evaluated in the mouse model of melanoma in order to obtain a promising 68Ga-DOTA-PDL1P immune PET probe. Methods: Gallium-68 (68Ga) was used to label DOTA-PDL1P, and its radiochemical purity and stability were evaluated by quality control. To evaluate its specific targeting performance, the cell uptake and blocking experiments were carried out in murine melanoma B16-F10 cells. The biodistribution experiment was performed in B16-F10 tumor-bearing mice to analyze the metabolism of the PET imaging agent in vivo. The Tumor uptake of 68Ga-DOTA-PDL1P in B16-F10 tumor-bearing mice was observed by PET/CT imaging, and the tumor/muscle (T/M) ratio was semi-quantitatively analyzed. In addition, radioautography was performed to further analyze the tumor uptake of 68Ga-DOTA-PDL1P probe. Tumor cell proportion score (TPS) and combined positive score (CPS) were used to analyze the immunohistochemical staining results to evaluate the expression of PD-L1 in tumor tissues. Results: The labeling efficiency and radiochemical purity of 68Ga-DOTA-PDL1P were more than 99%, and the radiochemical purity of 68Ga-DOTA-PDL1P was more than 90% after 3 h of incubation in PBS and fetal bovine serum. Cellular uptake results showed that 68Ga-DOTA-PDL1P could be specifically taken up by B16-F10 cells, and the specific uptake could be blocked by PD-L1P peptide competitive binding. Biodistribution assay showed that 68Ga-DOTA-PDL1P was mainly excreted through the urinary system. The results of microPET/CT imaging of tumor-bearing mice showed a high uptake of 68Ga-DOTA-PDL1P in tumor tissues, and the T/M ratio was 6.7. The autoradiography results confirmed that 68Ga-DOTA-PDL1P high uptake in the tumor was consistent with the PD-L1 positive area of immunohistochemical staining, which proved that 68Ga-DOTA-PDL1P could specifically bind to PD-L1 positive malignant tumor cells. Conclusion: The novel 68Ga-DOTA-PDL1P PET imaging agent synthesized in this study has good stability and can specifically target PD-L1 positive tumor cells, which is a promising new immune PET probe targeting PD-L1 protein.

Preparation and Bioevaluation of 18F-Labeled Small-Molecular Radiotracers via Sulfur(VI) Fluoride Exchange Chemistry for Imaging of Programmed Cell Death Protein Ligand 1 Expression in Tumors

Novel Dual-Function Near-Infrared II Fluorescence and PET Probe for Tumor Delineation and Image-Guided Surgery.

Design and Biological Evaluation of Small-Molecule PET-Tracers for Imaging of Programmed Death Ligand 1

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Synthesis and Biological Evaluation of Novel F-18 Labeled Pyrazolo[1,5-A]pyrimidine Derivatives: Potential PET Imaging Agents for Tumor Detection.

Linear Peptide-Based PET Tracers for Imaging PD-L1 in Tumors

The synthesis of a novel molecular imaging probe 68Ga-DOTA-PDL1P and application in mouse model of melanoma

Synthesis and Preliminary Evaluations of [18F]fluorinated Pyridine-2- carboxamide Derivatives for Targeting PD-L1 in Cancer

Preclinical Evaluation of a Fluorine-18 Labeled Probe for the Detection of the Expression of PSMA Level in Cancer

Design, synthesis and evaluation of novel prostate-specific membrane antigen-targeted aryl [ 18 F]fluorosulfate PET tracers

Immuno-SPECT/PET Imaging with Radioiodinated Anti-Pd-l1 Antibody to Evaluate PD-L1 Expression in Immune-Competent Murine Models and PDX Model of Lung Adenocarcinoma.

Design, Synthesis and Evaluation of Novel Prostate-Specific Membrane Antigen-Targeted Aryl [18f]fluorosulfate Pet Tracers

Preparation and bioevaluation of a 99mTc-labeled small-molecular radiotracer for PD-L1 imaging

One-Step 18F-Labeling and Preclinical Evaluation of Prostate-Specific Membrane Antigen Trifluoroborate Probes for Cancer Imaging

A novel 68Ga-labeled cyclic peptide molecular probe based on the computer-aided design for noninvasive imaging of PD-L1 expression in tumors

Quantitative, preclinical PET of translocator protein expression in glioma using 18F-N-fluoroacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyaniline

Bioorthogonal Diels-Alder Click Chemistry-Based Pretargeted PET Imaging Strategy for Monitoring Programmed Death-Ligand 1 Expression

Preclinical Evaluation of a Novel TSPO PET Ligand 2-(7-butyl-2-(4-(2-[18f]fluoroethoxy)phenyl)-5-methylpyrazolo[1,5-a]pyrimidin-3-yl)-n,n-diethylacetamide (18F-VUIIS1018A) to Image Glioma.

Optimization of Precursor Synthesis Conditions of (2S,4S)4–[18F]FPArg and Its Application in Glioma Imaging

Synthesis and Preclinical Evaluation of a 68Ga-Labeled Adnectin, 68Ga-BMS-986192, as a PET Agent for Imaging PD-L1 Expression

Optimization and automation of the radiosynthesis of [18F]Lu-LuFL as a clinically useful PET ligand targeting FAP for tumor imaging